# Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

> **NCT06980948** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sangamo Therapeutics** · enrollment: 27 (estimated)

## Conditions studied

- Chronic Neuropathic Pain

## Interventions

- **GENETIC:** ST-503
- **PROCEDURE:** Sham (No Treatment)

## Key facts

- **NCT ID:** NCT06980948
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2027-07
- **Final completion:** 2028-07
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06980948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06980948, "Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06980948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*